Betidamino acid scan of the GnRH antagonist acyline

Journal of Medicinal Chemistry

Volumn 40, Issue 23, 1997, Pages 3739-3748

  Jiang, Guangcheng ^a,b   Miller, Charleen ^a   Koerber, Steven C ^a   Porter, John ^a,c   Craig, A Grey ^a   Bhattacharjee, Sheela ^a,d   Kraft, Patricia ^a,d   Burris, Thomas P ^a,d   Campen, Carolyn A ^a,d   Rivier, Catherine L ^a   Rivier, Jean E ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b Ferring Pharmaceuticals AS   (Denmark)

^c Alanex Corporation   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLINE; AZALINE B; BETIDAMINO ACID DERIVATIVE; GLYCINE DERIVATIVE; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; UNCLASSIFIED DRUG;

ADENOHYPOPHYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHIRALITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FEMALE; HISTAMINE RELEASE; HYDROPHILICITY; LUTEINIZING HORMONE RELEASE; MALE; NONHUMAN; OVULATION INHIBITION; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEREOISOMERISM; SUBCUTANEOUS DRUG ADMINISTRATION;

AMIDES; AMINO ACIDS; ANIMALS; FEMALE; GONADOTROPIN-RELEASING HORMONE; MALE; OLIGOPEPTIDES; PITUITARY GLAND, ANTERIOR; RATS;

EID: 9844268498     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970024p     Document Type: Article

References (48)

1. Rivier, J. Novel antagonists of GnRH: a compendium of their physicochemical properties, activities, relative potencies and efficacy in humans. In Proceedings of the 3rd International Symposium on GnRH Analogues in Cancer and Human Reproduction; GnRH Analogues. The State of the Art 1993; Lunenfeld, B., Insler, V., Eds.; The Parthenon Publishing Group: Carnforth, Lancaster, 1993; pp 13-26.
2. Karten, M. J.; Hook, W. A.; Siraganian, R. P.; Coy, D. H.; Folkers, K.; Rivier, J. E.; Roeske, R. W. In vitro histamine release with LHRH analogs. In LHRH and Its Analogs, Contraceptive and Therapeutic Applications, Part 2; Vickery, B. H., Nestor, J., Eds.; MTP Press: Lancaster, 1987; pp 179-190.
3. Dutta, A. S. Luteinizing hormone-releasing hormone (LHRH) antagonists. Drugs Future 1988, 13, 43-57.
4. Karten, M. J.; Hoeger, C. A.; Hook, W. A.; Lindbert, M. C.; Naqvi, R. H. The development of safer GnRH antagonists: strategy and status. In Recent Progress on GnRH and Gonadal Peptides; Bouchard, P., Haour, F., Franchiniont, P., Schatz, B., Eds.; Elsevier: Paris, France, 1990; pp 147-158.
5. Lunenfeld, B.; Insler, V. GnRH Analogues. The State of the Art 1993. The Parthenon Publishing Group: Carnforth, Lancaster, 1993.
6. Rivier, J.; Porter, J.; Rivier, C.; Perrin, M.; Corrigan, A.; Hook, W. A.; Siraganian, R. P.; Vale, W. W. New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. J. Med. Chem. 1986, 29, 1846-1851.
7. 6 forms of the LH-RH antagonist Cetrorelix (SB-75). Int. J. Pept. Protein Res. 1995, 45, 410-417.
8. ω-triazolylornithine, -lysine or -para-aminophenylalanine residues at positions 5 and 6. J. Med. Chem. 1992, 35, 4270-4278.
9. 5 substitution in luteinizing hormone-releasing hormone antagonists. J. Med. Chem. 1993, 36, 928-933.
10. Rivier, J. E.; Jiang, G.-C.; Koerber, S. C.; Porter, J.; Craig, A. G.; Hoeger, C. Betidamino acids: Versatile and constrained scaffolds for drug discovery, Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2031-2036.
11. Bock, M. G.; DiPardo, R. M.; Evans, B. E.; Rittle, K. E.; Whitter, W. L.; Veber, D. F.; Anderson, P. S.; Freidinger, R. M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J. Med. Chem. 1989, 32, 13-16.
12. Katritzky, A. R.; Urogdi, L.; Mayence, A. Benzotriazole-assisted synthesis of monoacyl α-aminoglycines. J. Chem. Soc., Chem. Commun. 1989, 337-338.
13. Katritzky, A. R.; Urogdi, L.; Mayence, A. Benzotriazole-assisted synthesis of monoacyl aminals and their peptide derivatives. J. Org. Chem. 1990, 55, 2206-2214.
14. Qasmi, D.; René, L.; Badet, B. An α-aminoglycine derivative suitable for solid-phase peptide synthesis using Fmoc strategy. Tetrahedron Lett. 1993, 34, 3861-3862.
15. Rivier, J. E.; Jiang, G.; Porter, J.; Hoeger, C.; Craig, A. G.; Corrigan, A.; Vale, W.; Rivier, C. L. GnRH antagonists: novel members of the azaline B family. J. Med. Chem. 1995, 38, 2649-2662.
16. Rivier, J. E.; Jiang, G.-C.; Simon, L.; Koerber, S. C.; Porter, J.; Craig, A. G.; Hoeger, C. A. Betidamino acids: Versatile and constrained scaffolds for drug discovery. In Peptides: Chemistry, Structure and Biology, Proceedings of the The 14th American Peptide Symposium; Kaumaya, P. T. P., Hodges, R. S., Eds.; Mayflower Scientific Ltd.: England, 1996; pp 275-277.
17. Jiang, G.-C.; Simon, L.; Rivier, J. E. Orthogonally protected N-methyl-substituted α-aminoglycines. Protein Pept. Lett. 1996, 3, 219-224.
18. Miller, C.; Rivier, J. Peptide chemistry: Development of high-performance liquid chromatography and capillary zone electrophoresis. Biopolymers 1996, 40, 265-317.
19. Schmidt, A. B.; Fine, R. M. A CFF91-based continuum solvation model: Solvation free energies of small organic molecules and conformations of the alanine dipeptide in solution. Mol. Sim. 1994, 13, 347-365.
20. Hoeger, C. A.; Jiang, G.-C.; Koerber, S. C.; Reisine, T.; Liapakis, G.; Rivier, J. E. Betide based strategy for the design of selective somatostatin analogs. In Peptides: Chemistry, Structure and Biology, Proceedings of the The 14th American Peptide Symposium; Kaumaya, P. T. P., Hodges, R. S., Eds.; Mayflower Scientific Ltd.: England, 1996; pp 635-636.
21. Karten, M. J.; Rivier, J. E. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocrine Rev. 1986, 7, 44-66.
22. Karten, M. J. An overview of GnRH antagonists development: Two decades of progress. In Modes of Action of GnRH and GnRH Analogs; Crowley, W. F., Jr., Conn, P. M., Eds.; Springer-Verlag: New York, 1992; pp 277-297.
23. Rivier, J.; Brown, M.; Rivier, C.; Ling, N.; Vale, W. Hypothalamic hypophysiotropic hormones: review on the design of synthetic analogs. In Peptides 1976; Loffet, A., Ed.; Editions de l'Universites: Bruxelles, Belgium, 1976; pp 427-521.
24. Rivier, J.; Rivier, C.; Galyean, R.; Miranda, A.; Miller, C.; Craig, A. G.; Yamamoto, G.; Brown, M.; Vale, W. Single point D-substituted corticotropin releasing factor analogs: Effects on potency and physicochemical characteristics. J. Med. Chem. 1993, 36, 2851-2859.
25. 8]-somatostatin: An analog of somatostatin more potent than the native molecule. Biochem. Biophys. Res. Commun. 1975, 65, 746-751.
26. Monahan, M.; Amoss, M.; Anderson, H.; Vale, W. Synthetic analogs of the hypothalamic luteinizing hormone releasing factor with increased agonist or antagonist properties. Biochemistry 1973, 12, 4616-4620.
27. Rizo, J.; Koerber, S. C.; Bienstock, R. J.; Rivier, J.; Gierasch, L. M.; Hagler, A. T. Con format ional analysis of a highly potent, constrained gonadotropin-releasing hormone antagonist. II. Molecular Dynamics simulations. J. Am. Chem. Soc. 1992, 114, 2860-2871.
28. Bienstock, R. J.; Rizo, J.; Koerber, S. C.; Rivier, J. E.; Hagler, A. T.; Gierasch, L. M. Conformational analysis of a highly potent dicyclic gonadotropin-releasing hormone antagonist by nuclear magnetic resonance and molecular dynamics. J. Med. Chem. 1993, 36, 3265-3273.
29. Rivier, J.; Rivier, C.; Perrin, M.; Porter, J.; Vale, W. Application of the Mansch approach to design GnRH analogs using Topliss' manual method. In Peptides 1980; Brunfeldt, K., Ed.; Scriptor: Copenhagen, Denmark, 1981; pp 566-571.
30. Folkers, K.; Bowers, C. Y.; Kubiak, T.; Stepinski, J. Antagonists of the luteinizing hormone releasing hormone with pyridylalanines which completely inhibit ovulation at nanogram dosage. Biochem. Biophys. Res. Commun. 1983, 111, 1089-1095.
31. Rivier, J.; Rivier, C.; Perrin, M.; Porter, J.; Vale, W. LHRH analogs as antiovulatory agents. In LHRH and Its Analogs-Contraceptive and Therapeutic Applications. Advances in Reproduction; Vickery, B. H., Nestor, J. J., Jr., Hafez, E. S. E., Eds.; MTP Press: Lancaster, 1984; pp 11-22.
32. Rivier, J.; Varga, J.; Porter, J.; Perrin, M.; Haas, Y.; Corrigan, A.; Rivier, C.; Vale, W.; Struthers, S.; Hagler, A. Potent conformationally constrained analogs of GnRH. In Peptides: Structure and Function; Proceedings of the The Ninth American Peptide Symposium; Deber, C. M., Hruby, V. J., Kopple, K. D., Eds.; Pierce Chemical Co.: Rockford, IL, 1986; pp 541-544.
33. Perrin, M. H.; Haas, Y.; Rivier, J. E.; Vale, W. W. GnRH binding to rat anterior pituitary membrane homogenates: Comparison of antagonists and agonists using radiolabeled antagonist and agonist. Mol. Pharmacol. 1983, 23, 44-51.
34. Coy, D. H.; Kastin, A. J.; Schally, A. V.; Morin, O.; Caron, N. G.; Labrie, F.; Walker, J. M.; Fertel, R.; Berntson, G. G.; Sandman, C. A. Synthesis and opioid activities of stereoisomers and other D-amino acid analogs of methoionine-enkephalin. Biochem. Biophys. Res. Commun. 1976, 73, 632-638.
35. Hocart, S. J.; Nekola, M. V.; Coy, D. H. Improved antagonists of luteinizing hormone-releasing hormone modified in position 7. J. Med. Chem. 1985, 28, 967.
36. Rivier, J.; Varga, J.; Porter, J.; Perrin, M.; Rivier, C.; Vale, W.; Struthers, S.; Hagler, A. Design of cyclic GnRH antagonists. In Proceedings of the The GnRH Satellite Symposium, 7th International Congress of Endocrinology; Endocrinology; Elsevier Science Publishers B.V., Biomedfical Division, Amsterdam, 1984.
37. Fujino, M.; Kobayashi, S.; Obayashi, M.; Sinagawa, S.; Fukuda, T.; Kitada, C.; Nakayama, R.; Yamazaki, I.; White, W. F.; Rippel, R. H. Structure-activity relationships in the C-terminal part of luteinizing hormone releasing hormone (LH-RH). Biochem. Biophys. Res. Commun. 1972, 49, 863-869.
38. Karten, M. J.; Rivier, J. E. GnRH analog design Structure-function studies toward the development of agonists and antagonists: Rationale and perspective. Endocrine Rev. 1986, 7, 44-66.
39. ω-cyanoguanidino moieties. J. Med. Chem. 1991, 34, 2395-2402.
40. Kornreich, W.; Anderson, H.; Porter, J.; Vale, W.; Rivier, J. Peptide N-alkylamides by solid-phase synthesis. Int. J. Pept. Protein. Res. 1984, 25, 414-420.
41. Stewart, J. M.; Young, J. D. Solid Phase Peptide Synthesis, 2nd ed.; Pierce Chemical Company: Rockford, IL, 1984; p 176.
42. Le Nguyen, D.; Rivier, J. Use of carboethoxysulfenyl chloride (Sce-Cl) for disulfide bond formation. Int. J. Pept. Protein Res. 1986, 27, 285-292.
43. Kaiser, E.; Colescott, R. L.; Bossinger, C. D.; Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970, 34, 595-598.
44. Rivier, J.; McClintock, R.; Galyean, R.; Anderson, H. Reversed phase HPLC: Preparative purification of synthetic peptides. J. Chromatogr. 1984, 288, 303-328.
45. Corbin, A.; Beattie, C. W. Inhibition of the pre-ovulatory proestrous gonadotropin surge, ovulation and pregnancy with a peptide analogue of luteinizing hormone releasing hormone. Endocr. Res. Commun. 1975, 2, 1-23.
46. Rivier, C.; Rivier, J.; Perrin, M.; Vale, W. Comparison of the effect of several GnRH antagonists on LH secretion, receptor binding and ovulation. Biol. Reprod. 1983, 29, 374-378.
47. Rivier, C.; Rivier, J.; Vale, W. Stress-induced inhibition of reproductive functions: Role of endogenous corticotropin-releasing factor. Science 1986, 231, 607-609.
48. Rivier, C.; Vale, W. In the rat, interleukin-1α acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion. Endocrinology 1989, 124, 2105-2109.